Is Wegovy's Price Increasing — and What UK Patients Should Know

The misconception worth clearing up first

A lot of people searching for Wegovy price information have already spotted a low figure somewhere and assumed that's the market rate. It almost certainly isn't the full cost. The figure quoted by some providers covers the medicine alone, with consultation fees, prescription charges, delivery and ongoing clinical support billed separately or simply not included. When those items are added, the actual monthly spend often lands higher than the headline suggested. That's not unusual in private healthcare, but it is frustrating when you're trying to budget honestly.

There's also a widespread belief that prices are set to fall as supply improves. That may happen over time, but it hasn't yet. You can see the full picture of what changed and why on our Wegovy price increase 2025 page, which covers Novo Nordisk's own pricing movements to UK wholesalers through late 2025 and into 2026 and how that has been passed on. The NICE appraisal of semaglutide (TA875) established clinical criteria for NHS access, but the NHS pathway involves long waits for most people, private pricing reflects that unmet demand.

So when people ask whether Wegovy's price is increasing: broadly, yes, it has been. Whether it increases further or stabilises depends on manufacturer decisions, supply chains and competition that no private provider controls. What you can control is understanding exactly what you're paying for.

What 'rising costs' looks like in practice across providers

Reported UK private prices for Wegovy injection have ranged from roughly £149 to well above £300 per month at maintenance doses, as widely reported since August 2025 when Eli Lilly's parallel price rise for Mounjaro drew attention to GLP-1 market pricing more generally. Wegovy's price trajectory has been similar.

What separates providers at similar price points isn't usually the medicine itself, it's everything around it. Some clinics charge separately for each titration review. Others require a monthly subscription that continues regardless of whether you actually order. Delivery fees, ID verification steps and clinical aftercare costs can all be additional. The NHS England guidance on weight-management injections makes clear that safe use of these medicines involves ongoing clinical oversight, not just an initial sign-off, so that oversight has to sit somewhere in the cost.

You can read more about how the market has moved on our Wegovy price in the UK page, which covers current private pricing context in more detail. For the broader story of how the Wegovy price increase unfolded through 2025, our 2025 price-increase timeline sets out what changed and when.

Where nume sits, and why we say it plainly

A real clinician, not a queue for automated software, reads every consultation at nume the same day. A GPhC-registered Independent Prescriber reviews your answers, your health history and your eligibility before anything is approved. Our pharmacy's GPhC registration (number 9012878, verifiable on the GPhC register) is public and checkable in under a minute.

We charge one price that includes the consultation, the prescription, the medicine and free next-working-day tracked delivery via DPD. There are no add-on fees and no subscription, every repeat order goes through a fresh clinical review. Current treatment pricing is on our weight-loss treatments page. We don't print per-pen prices in articles because they shift; the page is always current.

We are not the cheapest option. That's a deliberate choice. The clinical infrastructure we run (same-day prescriber review, live weight verification, photo-ID checks, GP notification in line with GPhC guidance) costs more to operate than a quick online form with a checkbox. We think that cost is justified. You should decide whether it is for you. Our about us page explains the service in full, and our clinical team is named and publicly accountable.

Why 'cheapest' is the wrong question for a prescription medicine

Wegovy is a prescription-only medicine. The MHRA has documented (and continues to investigate) widespread online sale of fake GLP-1 pens, some of which have contained insulin rather than semaglutide. Large seizures of counterfeit stock have been made across the UK, and the supply of genuinely licensed product depends on verifiable pharmacy registration and regulated supply chains.

If you're comparing providers on price alone, the question worth asking is: can I verify this pharmacy on the GPhC register? Is there a named prescriber reviewing my case? Are they sourcing through the authorised UK supply chain? The MHRA's Yellow Card service exists partly so that patients can report suspect sellers, a reminder that the regulator treats this as a live risk, not a historic one.

The cheapest listing often means something was left out: clinical review, genuine stock, or post-purchase support when questions arise. Our FAQs cover the most common queries patients have after starting treatment. If a price looks considerably lower than the market range, it's worth reading about the Wegovy price decrease claims that circulate online, because that gap is worth understanding before you commit. A modest saving on a prescription medicine isn't the measure that keeps you safe.

If you'd like to understand whether Wegovy is clinically suitable for you (without any obligation) the right starting point is a conversation with our prescribers.

Speak to our prescribers and start your free consultation.